Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes

Cancer Research

Volumn 60, Issue 18, 2000, Pages 5223-5227

  Lu, J ^a   Celis, E ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ALGORITHM; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; COMPUTER SYSTEM; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EPITOPE MAPPING; HUMAN; HUMAN CELL; INTERNET; PRIORITY JOURNAL; SOLID TUMOR;

ALGORITHMS; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIGEN PRESENTATION; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TRANSFORMED; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HLA-B7 ANTIGEN; HUMAN; IMMUNOTHERAPY, ADOPTIVE; INTERNET; LYMPHOCYTE ACTIVATION; NEOPLASMS; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0034665127     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. EBV specific CTL: A model for immune therapy
2. Human turnout antigens recognized by T cells: New perspectives for anti-cancer vaccines?
3. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy
4. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes
5. Tumor antigens recognized by T lymphocytes
6. Adoptive cellular immunotherapy for EBV lymphoproliferative disease
7. Vaccination of melanoma patients with peptide- or tumor lysatepulsed dendritic cells
8. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
9. Vaccination with mage-3A1 peptidepulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
10. Use of minorinfiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A report
11. The biochemistry and cell biology of antigen processing and presentation
12. Antigen processing and presentation by the class I major histocompatibility complex
13. MHC class I-restricted antigen processing: Lessons from natural ligands
14. CEA-related antigens: Molecular biological and clinical significance
15. CEA gene family: Molecular biology and clinical perspectives
16. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine
17. Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte
18. Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells
19. The multi-epitope approach for immunotherapy for cancer: Identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors
20. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide sidechains
21. SYFPEITHI: Database for MHC ligands and peptide motifs
22. Peptide motifs of HLA-A3, -A24, and -B7 molecules as determined by pool sequencing
23. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised
24. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ
25. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription
26. Proliferating dendritic cell progenitors in human blood
27. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α
28. In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells
29. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles
30. Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules
31. Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein
32. Human H-Y: A male-specific histocompatibility antigen derived from the SMCY protein
33. Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes
34. Identification of subdominant CTL epitopes of the gp100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells
35. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24
36. Identification of gp100-derived, melanoma-specific cytotoxic T- lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells
37. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays
38. Termination of peripheral tolerance to a T cell epitope by heteroclitic antigen analogues
39. Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ minors
40. A Phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
41. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
42. Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo
43. Induction of antitumor immunity using bone marrow-generated dendritic cells
44. Bone marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic antitumor immunity
45. Generation of T-cell immunity to a marine melanoma using MART-engineered dendritic cells